Business
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger: VRNA, BPMC, DALN, and RGLD
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger: VRNA, BPM...
About this update from Red Lake Gold Inc
[{"type":"text","content":"$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger: VRNA, BPMC, DALN, and RGLD\n\n\n\n $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger: VRNA, BPMC, DALN, and RGLD\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n\n\n\n\n $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger: VRNA, BPMC, DALN, and RGLD\n \n\n PR Newswire\n \n\n\n\n\n\n NEW YORK\n \n\n ,\n \n\n July 18, 2025\n \n\n /PRNewswire/ --\n \n Class Action Attorney\n \n\n\n Juan Monteverde\n \n\n\n with\n \n\n Monteverde & Associates PC\n \n (the \"M&A Class Action Firm\"), has recovered millions of dollars for shareholders and is recognized as a\n \n Top 50 Firm\n \n in the 2024 ISS Securities Class Action Services Report. We are headquartered at the\n \n Empire State Building\n \n in\n \n New York City\n \n and are investigating\n \n\n\n\n Verona Pharma plc (NASDAQ:\n \n\n\n VRNA\n \n\n\n )\n \n related to its sale to Merck Sharp & Dohme LLC for\n \n $107.00\n \n per American Depository Shares.\n \n\n\n\n Click here for more information\n \n\n\n https://monteverdelaw.com/case/verona-pharma-plc/\n \n\n\n https://monteverdelaw.com/case/dnow-inc/\n \n\n .\n \n\n It is free and there is no cost or obligation to you.\n \n\n\n\n\n Blueprint Medicines Corporation (NASDAQ:\n \n\n\n BPMC\n \n\n\n )\n \n related to its sale to Sanofi, S.A. Under the terms of the proposed transaction, Sanofi will pay\n \n $129.00\n \n per share in cash at closing, and Blueprint shareholders also will receive one non-tradeable contingent value right (\"CVR\") entitling the holder to receive two potential milestone payments of\n \n $2.00\n \n and\n \n $4.00\n \n per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808.\n \n\n\n\n Click here for more information\n \n\n\n https://monteverdelaw.com/case/blueprint-medicines-corporation-2/\n \n\n\n .\n \n\n It is free and there is no cost or obligation to you.\n \n\n\n\n\n DallasNews Corporation (NASDAQ:\n \n\n\n DALN\n \n\n\n )\n \n...